TCIM
IOVA icon

TIAA CREF Investment Management’s Iovance Biotherapeutics IOVA Stock Holding History

TIAA CREF Investment Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$2.5M Sell
263,171
-29,478
-10% -$286K ﹤0.01% 1880
2018
Q4 		$2.59M Sell
292,649
-3,629
-1% -$35K ﹤0.01% 1805
2018
Q3 		$3.33M Sell
296,278
-358,892
-55% -$5.09M ﹤0.01% 1852
2018
Q2 		$8.39M Buy
655,170
+162,653
+33% +$2.38M 0.01% 1265
2018
Q1 		$8.32M Buy
492,517
+170,591
+53% +$2.58M 0.01% 1229
2017
Q4 		$2.58M Buy
321,926
+63,135
+24% +$507K ﹤0.01% 1994
2017
Q3 		$2.01M Buy
258,791
+79,552
+44% +$503K ﹤0.01% 2165
2017
Q2 		$1.32M Buy
179,239
+35,599
+25% +$226K ﹤0.01% 2413
2017
Q1 		$1.07M Sell
143,640
-6,245
-4% -$45.8K ﹤0.01% 2480
2016
Q4 		$1.04M Sell
149,885
-4,095
-3% -$28.2K ﹤0.01% 2505
2016
Q3 		$1.27M Buy
153,980
+7,026
+5% +$59.4K ﹤0.01% 2414
2016
Q2 		$1.19M Sell
146,954
-69
-0% -$433 ﹤0.01% 2420
2016
Q1 		$747K Hold
147,023
– – ﹤0.01% 2623
2015
Q4 		$1.14M Sell
147,023
-7,494
-5% -$52K ﹤0.01% 2507
2015
Q3 		$890K Buy
154,517
+21,561
+16% +$168K ﹤0.01% 2632
2015
Q2 		$1.22M Buy
+132,956
New +$1.48M ﹤0.01% 2606

Other funds holding IOVA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TIAA CREF Investment Management's IOVA Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Iovance Biotherapeutics (IOVA) stake by 10% in Q1 2019, selling an estimated $286K and leaving 263,171 shares worth $2.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1880.

TIAA CREF Investment Management first reported a position in IOVA in Q2 2015 and has held it in 16 quarters since. The position peaked at $8.39M in Q2 2018. 153 funds tracked by Wall St. Rank hold IOVA as of Q1 2019.

  • TIAA CREF Investment Management held 263,171 shares of Iovance Biotherapeutics worth $2.5M as of Q1 2019.
  • TIAA CREF Investment Management sold 29,478 Iovance Biotherapeutics shares in Q1 2019, an estimated $286K.
  • Iovance Biotherapeutics made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #1880 holding.
  • TIAA CREF Investment Management first reported a position in Iovance Biotherapeutics in Q2 2015 and has held it in 16 quarters since.
  • TIAA CREF Investment Management's Iovance Biotherapeutics position peaked at $8.39M in Q2 2018.
  • 153 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.